In a pre-clinical study, fibrinogen increased the death of mouse brain neurons, suggeting fibrin can have similar toxic effects on neurons.
List view / Grid view
Alzheimer's disease (AD)
The study found that deleting the ABI3 gene in mice increased plaques and inflammation in the brain, suggesting avenues for new treatments.
Turning off NHE6 in mice in pre-clinical studies prevented amyloid beta aggregation, a key feature of Alzheimer's disease, pointing to new therapies.
Scientists have developed a novel technique for the targeted clearance of senescent cells to improve treatments for ageing and other conditions.
Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
Axitinib, a common chemotherapy drug, restored memory and cognitive function in mouse models, representing a potential Alzheimer’s treatment.
Guided by precise biomarker tests, therapeutic vaccines targeting the pathology of neurodegenerative disease could provide solutions to the impending global crisis in dementia. As Dr Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director of AC Immune, describes here, current work is both establishing the targets that those vaccines must address…
In a new study, researchers at Brigham and Women’s Hospital, US, successfully developed stem cell-derived neuronal profiles from individual patients. Here, Drug Target Review’s Victoria Rees explores the findings and how these new models can help to advance precision and personalised medicine.
Scientists have discovered drug targets in the neural circuits that encode memories, paving the way for the treatment of brain disorders.
Researchers have turned human stem cells into brain cells to create a new model that can predict cognitive decline rate on an individualised level.
Dr Ronald G Crystal, Professor and Chairman of the Department of Genetic Medicine, Weill Cornell Medical College, spoke to Drug Target Review’s Victoria Rees about his research into Alzheimer’s disease and why gene therapies represent a promising area of research for neurodegenerative conditions.
Scientists have developed a new strategy using brain-wide genome-editing technology that reduced Alzheimer’s disease pathologies in mice.
Researchers have created a new method to quantify protein droplets involved in neurodegenerative diseases, enhancing the study of treatments.